DIA Biosimilars 2013

Multiple Myeloma Research Foundation

Modulation Therapeutics receives $500,000 from MMRF for cancer treatment

Monday, June 11, 2012 11:54 AM

The Multiple Myeloma Research Foundation (MMRF) has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics, an early-stage pharmaceutical company which has licensed MTI-101 from the Moffitt Cancer Center.

More... »

Cenduit: Now with Patient Reminders

CEO of the Multiple Myeloma Research Foundation makes the TIME 100 list

Friday, April 22, 2011 12:19 PM

TIME has named Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation (MMRF), to the 2011 TIME 100, the magazine’s annual list of the 100 most influential people in the world.

More... »

CRF Health – eCOA Forum

Multiple Myeloma Research Foundation’s Edward Jay Phillips deceased

Monday, April 11, 2011 12:31 PM

The Multiple Myeloma Research Foundation (MMRF) mourns the loss of board member Edward (“Eddie”) Jay Phillips, who, on April 8, 2011 died of multiple myeloma. Phillips, son of "Dear Abby" and creator of Belvedere Vodka, had battled multiple myeloma for nine years.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs